

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-18. (Cancelled)

19. (New) A conjugate having the general formula



wherein

P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa;

NAT represents a nuclide activation therapy agent;

L represents a linker moiety capable of linking the polymer to the neutron capture therapy agent; and

n represents an integer from 1-1,000;

and wherein the conjugate further comprises a chemotherapeutic agent attached to the polymer via the linker moiety L.

20. (New) A conjugate as claimed in claim 19, wherein the polymer is a 2-hydroxypropylmethacrylamide-methacrylate copolymer.

21. (New) A conjugate as claimed in claim 19, wherein the polymer has a molecular weight of 5-100, preferably 10-70, more preferably 15-45, most preferably 20-40 kDa.

22. (New) A conjugate as claimed in claim 19, wherein the ratio of hydroxypropylmethacrylamide to methacrylate is from 20:1 to 1:1.

23. (New) A conjugate as claimed in claim 19, wherein the nuclide activation therapy agent is a neutron capture therapy agent.

24. (New) A conjugate as claimed in claim 23, wherein the neutron capture therapy agent contains at least one nuclide selected from 6Li , ^{10}B , ^{22}Na , ^{58}Co , ^{113}Cd , ^{126}I , ^{135}Xe , ^{148m}Pm , ^{149}Sm , ^{151}Eu , ^{155}Gd , ^{157}Gd , ^{164}Dy , ^{184}Os , ^{199}Hg , ^{230}Pa , ^{235}U and ^{241}Pu in sufficient quantity to undergo a

neutron capture reaction.

25. (New) A conjugate as claimed in claim 24, wherein the nuclide is ^{10}B .
26. (New) A conjugate as claimed in claim 23, wherein NAT represents a boronated amino acid or peptide, a modified carborane cage, a mercaptoborate, a boron-containing porphyrin or phthalocyanine, a boron-containing nucleic acid precursor, or a boron-containing foliate growth factor, hormone, radiation sensitizer, phosphates, phosphonate, phosphoramidates, cyclic thiourea derivative, amine, promazine, hydantoin or barbiturate.
27. (New) A conjugate as claimed in claim 19, wherein the NAT agent makes up 1-30%, preferably 5-10%, of the overall mass of the conjugate.
28. (New) A conjugate as claimed in claim 19, wherein the linker represents a linear or branched C₁₋₁₅ alkyl which may be saturated or unsaturated, optionally substituted by carbonyl, amide, hydroxyl or halogen; a peptide, preferably 1-10 amino acids in length, in which the amino acids may be further substituted with amino, thio, carboxyl, carboxamide or imidazole groups; or a covalent bond.
29. (New) A conjugate as claimed in claim 19, wherein n represents an integer from 1-500, preferably 1-100, particularly preferably 1-20.
30. (New) Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-BSMe)Gly-Phe-Leu-Gly-Paclitaxel [SEQ ID NO: 20].
31. (New) Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-BSMe)Gly-Phe-Leu-Gly-Doxorubicin [SEQ ID NO: 20].
32. (New) A pharmaceutical composition containing the conjugate as claimed in claim 19.
33. (New) A method of treating cancer which comprises administering to a patient in need thereof an effective amount of a medicament comprising the conjugate of claim 19.